Inflammatory Breast Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy
Conditions: Inflammatory Breast Cancer Interventions: Procedure: Breast conserving surgery; Procedure: Radical modified mastectomy Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 14, 2023 Category: Research Source Type: clinical trials

Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
Conditions: Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Neoplasms; Triple Negative Breast Neoplasms; Neoplasm Metastasis Interventions: Behavioral: Self-Administered Hypnosis; Behavioral: Self-Administered White Noise Hypnosis Sponsors: The University of Tennessee, Knoxville; Baylor University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER2 and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
Conditions: Metastatic Breast Cancer; Breast Cancer Interventions: Drug: Neratinib; Drug: Capmatinib Sponsors: M.D. Anderson Cancer Center; Celcuity, Inc.; Novartis; Puma Biotechnology, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 17, 2022 Category: Research Source Type: clinical trials

Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Inflammatory Carcinoma; Metastatic Triple-Negative Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8 Interventions: Drug: Dasatinib; Dietary Supplement: Icosapent Ethyl Sponsor: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 20, 2022 Category: Research Source Type: clinical trials

SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Breast Inflammatory Carcinoma; Metastatic Triple-Negative Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8 Interventions: Drug: Carboplatin; Biological: Pembrolizumab; Genetic: Transferrin Receptor-Targeted Liposomal p53 cDNA Sponsors: Northwestern University; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2021 Category: Research Source Type: clinical trials